Piriou A, Jacqueson A, Thévenin M, Warnet J M, Claude J R
Arch Toxicol Suppl. 1980;4:331-4. doi: 10.1007/978-3-642-67729-8_69.
The purpose of this work was to study if the steatogenic effect on the liver of Rifampicin, which is an inhibitor of the RNA polymerases DNA dependent in bacteria, can be prevented by an anabolic steroid: 19 nortestosterone phenylproprionate (19-NTPP) which probably stimulates the RNA polymerase activity in eukariotic cells. 19-NTPP (25 mg/kg/24 h, i.p.) was administered to male and both intact and ovariectomized female rats for 8 days prior to the administration of Rifampicin (400 mg/kg/24 h for 8 days). In male rats, 19-NTPP does not prevent the Rifampicin-induced fatty liver. On the contrary, in female rats, 19-NTPP exerts a partial protective effect in intact as well as in ovariectomized animals. These results show that the protective effect of 19-NTPP against Rifampicin fatty liver is less complete and little specific, comparated to the protective effect obtained against another steatogenic compound in female rats: alpha-Amanitin, which is a potent inhibitor of RNA polymerase II in eukariotic cells. In conclusion, the inhibitor effect of Rifampicin on the hepatic apolipoprotein biosynthesis appears as less specific and more intricate than the comparable effect of alpha-Amanitin.
本研究旨在探讨利福平(一种细菌中依赖DNA的RNA聚合酶抑制剂)对肝脏的致脂肪变性作用是否能被一种合成代谢类固醇:19-去甲睾酮苯丙酸酯(19-NTPP)所预防,19-NTPP可能会刺激真核细胞中的RNA聚合酶活性。在给予利福平(400mg/kg/24h,共8天)之前,对雄性大鼠以及完整雌性大鼠和去卵巢雌性大鼠腹腔注射19-NTPP(25mg/kg/24h,共8天)。在雄性大鼠中,19-NTPP不能预防利福平诱导的脂肪肝。相反,在雌性大鼠中,19-NTPP在完整雌性大鼠和去卵巢雌性大鼠中均发挥部分保护作用。这些结果表明,与在雌性大鼠中对另一种致脂肪变性化合物:α-鹅膏蕈碱(真核细胞中RNA聚合酶II的强效抑制剂)所获得的保护作用相比,19-NTPP对利福平脂肪肝的保护作用不太完全且特异性较低。总之,利福平对肝脏载脂蛋白生物合成的抑制作用似乎比α-鹅膏蕈碱的类似作用特异性更低且更复杂。